{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:57:07Z","timestamp":1791158227655,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T00:00:00Z","timestamp":1282608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00280-010-1428-4","type":"journal-article","created":{"date-parts":[[2010,8,23]],"date-time":"2010-08-23T07:42:10Z","timestamp":1282549330000},"page":"1299-1312","source":"Crossref","is-referenced-by-count":26,"title":["Satraplatin (JM-216) mediates G2\/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance"],"prefix":"10.1007","volume":"67","author":[{"given":"Murugan","family":"Kalimutho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Minutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Grelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Formosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Sancesario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,24]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23\u201330","journal-title":"J Clin Oncol"},{"key":"1428_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s002800100363","volume":"48","author":"S Hector","year":"2001","unstructured":"Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398\u2013406","journal-title":"Cancer Chemother Pharmacol"},{"key":"1428_CR3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1040-8428(01)00219-0","volume":"42","author":"B Desoize","year":"2002","unstructured":"Desoize B, Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317\u2013325","journal-title":"Crit Rev Oncol Hematol"},{"key":"1428_CR4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0014-5793(02)03347-1","volume":"529","author":"I Gourdier","year":"2002","unstructured":"Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y, Paul B (2002) Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529:232\u2013236","journal-title":"FEBS Lett"},{"key":"1428_CR5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.bjc.6603866","volume":"97","author":"CC Chen","year":"2007","unstructured":"Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC et al (2007) Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer 97:334\u2013344","journal-title":"Br J Cancer"},{"key":"1428_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP (1992) p53, guardian of the genome. Nature 358:15\u201316","journal-title":"Nature"},{"key":"1428_CR7","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/sj.bjc.6602215","volume":"91","author":"D Arango","year":"2004","unstructured":"Arango D, Wilson AJ, Shi Q et al (2004) Molecular mechanism of action and prediction of response to oxaliplatin in colorectal cancer. Br J Cancer 91:1931\u20131946","journal-title":"Br J Cancer"},{"key":"1428_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1568009033333727","volume":"3","author":"S Manic","year":"2003","unstructured":"Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P (2003) Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3:21\u201329","journal-title":"Curr Cancer Drug Targets"},{"key":"1428_CR9","first-page":"577","volume":"61","author":"N Mitsiades","year":"2001","unstructured":"Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I (2001) Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61:577\u2013581","journal-title":"Cancer Res"},{"key":"1428_CR10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jnci\/89.11.783","volume":"89","author":"O Micheau","year":"1997","unstructured":"Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 89:783\u2013789","journal-title":"J Natl Cancer Inst"},{"key":"1428_CR11","first-page":"25","volume":"1755","author":"ME Peter","year":"2008","unstructured":"Peter ME, Legembre P, Barnhart BC (2008) Does CD95 have tumor promoting activities? Biochim Biophys Acta 1755:25\u201336","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"1428_CR12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/13543784.14.8.1033","volume":"14","author":"MJ McKeage","year":"2005","unstructured":"McKeage MJ (2005) New-generation platinum drugs in the treatment of cisplatin resistant cancers. Expert Opin Investig Drugs 14(8):1033\u20131046","journal-title":"Expert Opin Investig Drugs"},{"key":"1428_CR13","first-page":"2581","volume":"53","author":"LR Kelland","year":"1993","unstructured":"Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53:2581\u20132586","journal-title":"Cancer Res"},{"issue":"9","key":"1428_CR14","first-page":"981","volume":"1","author":"SY Sharp","year":"1995","unstructured":"Sharp SY, Rogers PM, Kelland LR (1995) Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine platinum (IV) (JM-216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1(9):981\u2013989","journal-title":"Clin Cancer Res"},{"key":"1428_CR15","first-page":"541","volume":"70","author":"MR Moore","year":"1986","unstructured":"Moore MR, Troner MB, DeSimone P et al (1986) Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a southeastern cancer study group trial. Cancer Treat Res 70:541\u2013542","journal-title":"Cancer Treat Res"},{"key":"1428_CR16","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.1997.15.7.2691","volume":"15","author":"MJ McKeage","year":"1997","unstructured":"McKeage MJ, Raynaud F, Ward J et al (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5\u00a0days in patients with cancer. J Clin Oncol 15:2691\u20132700","journal-title":"J Clin Oncol"},{"key":"1428_CR17","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.1999.17.12.3822","volume":"17","author":"E Fokkema","year":"1999","unstructured":"Fokkema E, Groen HJM, Bauer J et al (1999) Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17:3822\u20133827","journal-title":"J Clin Oncol"},{"key":"1428_CR18","first-page":"4881","volume":"56","author":"D Fink","year":"1996","unstructured":"Fink D, Nebel S, Aebi S et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881\u20134886","journal-title":"Cancer Res"},{"key":"1428_CR19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0006-2952(02)00983-8","volume":"63","author":"E Fokkema","year":"2002","unstructured":"Fokkema E, Groen HJM, Helder MN et al (2002) JM216, JM118, and cisplatin induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63:1989\u20131996","journal-title":"Biochem Pharmacol"},{"key":"1428_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000084201","volume":"68","author":"CN Sternberg","year":"2005","unstructured":"Sternberg CN, Whelan P, Hetherington P et al (2005) Phase III trial of satraplatin, an oral platinum plus prednisone versus prednisone alone in patients with hormone-resistant prostate cancer. Oncology 68:2\u20139","journal-title":"Oncology"},{"key":"1428_CR21","doi-asserted-by":"crossref","first-page":"11026","DOI":"10.1021\/bi9909187","volume":"38","author":"A Vaisman","year":"1999","unstructured":"Vaisman A, Lim SE, Patrick SM et al (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 38:11026\u201311039","journal-title":"Biochemistry"},{"issue":"9","key":"1428_CR22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1054\/bjoc.1999.1169","volume":"82","author":"JRW Masters","year":"2000","unstructured":"Masters JRW, Twentyman P, Arlett C et al (2000) UKCCCR guidelines for the use of cell lines in cancer research. British J of Cancer 82(9):1495\u20131509","journal-title":"British J of Cancer"},{"key":"1428_CR23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-0320(19990201)35:2<145::AID-CYTO6>3.0.CO;2-2","volume":"35","author":"C Matteucci","year":"1999","unstructured":"Matteucci C, Grelli S, De Smaele E, Fontana C, Mastino A (1999) Identification of nuclei from apoptotic, necrotic, and viable lymphoid cells by using multiparameter flow cytometry. Cytometry 35:145\u2013153","journal-title":"Cytometry"},{"issue":"4","key":"1428_CR24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611\u2013622","journal-title":"Clin Chem"},{"key":"1428_CR25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00001813-199106000-00003","volume":"2","author":"GH Blijham","year":"1991","unstructured":"Blijham GH (1991) Chemotherapy of colorectal cancer. Anticancer Drugs 2:233\u2013245","journal-title":"Anticancer Drugs"},{"key":"1428_CR26","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont De","year":"2000","unstructured":"De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"key":"1428_CR27","first-page":"822","volume":"52","author":"LR Kelland","year":"1992","unstructured":"Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR (1992) Ammine\/amine platinum (IV) dicarboxylates: a novel class of platinum complexes exhibiting selective cytotoxicity to intrinsic cisplatin resistant human ovarian carcinoma cell lines. Cancer Res 52:822\u2013828","journal-title":"Cancer Res"},{"issue":"4","key":"1428_CR28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00280-007-0502-z","volume":"60","author":"K Wosikowski","year":"2007","unstructured":"Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M (2007) Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 60(4):589\u2013600","journal-title":"Cancer Chemother Pharmacol"},{"key":"1428_CR29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s002800050413","volume":"37","author":"M Ormerod","year":"1996","unstructured":"Ormerod M, O\u2019Neill C, Robertson D, Kelland LR, Harrap KR (1996) Cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463\u2013471","journal-title":"Cancer Chemother Pharmacol"},{"key":"1428_CR30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0320(19970101)27:1<54::AID-CYTO7>3.0.CO;2-L","volume":"27","author":"A Vaisman","year":"1997","unstructured":"Vaisman A, Varchenko M, Said I, Chaney SG (1997) Cell cycle changes associated with the formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27:54\u201364","journal-title":"Cytometry"},{"key":"1428_CR31","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/bjc.1998.230","volume":"77","author":"N Zaffaroni","year":"1998","unstructured":"Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R (1998) The induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin, sensitive and resistant human ovarian cancer cells. Br J Cancer 77:1378\u20131385","journal-title":"Br J Cancer"},{"key":"1428_CR32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bjc.1996.486","volume":"74","author":"CF O\u2019Neill","year":"1996","unstructured":"O\u2019Neill CF, Ormerod MG, Robertson D, Titley JC, Cumber-Walsweer Y, Kelland LR (1996) Apoptotic and non apoptotic cell death induced by cis and trans analogues of a novel ammine (cyclohexylamine) dihydroxodichloroplatinum (IV) complex. Br J Cancer 74:1037\u20131045","journal-title":"Br J Cancer"},{"key":"1428_CR33","first-page":"6703","volume":"48","author":"CM Sorenson","year":"1998","unstructured":"Sorenson CM, Eastman A (1998) Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48:6703\u20136707","journal-title":"Cancer Res"},{"key":"1428_CR34","first-page":"3311","volume":"8","author":"R Di Paola","year":"2002","unstructured":"Di Paola R (2002) To arrest or not to G2-M cell cycle arrest. Clin Can Res 8:3311\u20133314","journal-title":"Clin Can Res"},{"key":"1428_CR35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1006\/bbrc.2000.4231","volume":"280","author":"S Dan","year":"2001","unstructured":"Dan S, Yamori T (2001) Repression of cyclin B1 expression after treatment with Adriamycin, but not cisplatin in human lung cancer A549 cells. Biochem Biophys Res Commun 280:861\u2013867","journal-title":"Biochem Biophys Res Commun"},{"key":"1428_CR36","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1535-7163.MCT-05-0212","volume":"5","author":"C Voland","year":"2006","unstructured":"Voland C, Bord A, Peleraux A, Penarier G, Carriere D, Galiegue S, Cvitkovic E, Jbilo O, Casellas P (2006) Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 5:2149\u20132157","journal-title":"Mol Cancer Ther"},{"key":"1428_CR37","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.MCT-05-0011","volume":"4","author":"T Hata","year":"2005","unstructured":"Hata T, Yamamoto H, Ngan CY et al (2005) Role of p21waf1\/cip1 in effects of oxaliplatin in colorectal cancer cells. Mol Cancer Ther 4:1585\u20131594","journal-title":"Mol Cancer Ther"},{"key":"1428_CR38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1535-7163.169.3.2","volume":"3","author":"RL Hayward","year":"2004","unstructured":"Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI (2004) Enhanced oxaliplatin-induced apoptosis following antisense Bclxl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169\u2013178","journal-title":"Mol Cancer Ther"},{"key":"1428_CR39","first-page":"219","volume":"24","author":"P Marchetti","year":"2004","unstructured":"Marchetti P, Galla DA, Russo FP, Ricevuto E, Flati V, Porzio G, Ficorella C, Cifone MG (2004) Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 24:219\u2013226","journal-title":"Anticancer Res"},{"issue":"3","key":"1428_CR40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.phrs.2007.07.001","volume":"56","author":"L Rossi","year":"2007","unstructured":"Rossi L, Bonmassar E, Faraoni I (2007) Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56(3):248\u2013253","journal-title":"Pharmacol Res"},{"issue":"5","key":"1428_CR41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccr.2007.10.028","volume":"12","author":"H Hermeking","year":"2007","unstructured":"Hermeking H (2007) p53 enters the microRNA world. Cancer Cell 12(5):414\u2013418","journal-title":"Cancer Cell"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1428-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1428-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1428-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T23:35:13Z","timestamp":1685748913000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1428-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,24]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1428-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,24]]}}}